Market Overview

Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

Share:
Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises

The Street’s becoming increasingly — albeit reluctantly — bullish on Biogen Inc (NASDAQ: BIIB).

“While we have all the enthusiasm that goes with catching a falling knife here, we believe BIIB shares are too ‘cheap’ to sit on the sidelines,” Baird Equity Research analyst Brian Skorney said in a Wednesday note.

The Rating

Skorney upgraded Biogen from Neutral to Outperform and maintained a $323 price target.

The Thesis

The analyst considers Biogen better suited than Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Gilead Sciences, Inc. (NASDAQ: GILD) to provide upside optionality at its present valuation. (See Skorney's track record here.) 

For one, its multiple sclerosis franchise appears stable against Street forecasts, despite enduring susceptibility to pricing and market share pressures, the analyst said. 

At the same time, Skorney considers Spinraza underappreciated and “a meaningful growth engine" for Biogen. 

“We believe the threat of gene therapy has kept its contribution to the valuation suppressed, but believe this should not be the case and could even argue gene therapy could increase Spinraza's long-term sales, as the two should be used in combination and could result in significantly increasing prevalence by extending survival." 

Biogen is well-positioned for acquisition as either a buyer or a seller, Skorney said. Its relatively small potential revenue deficits would allow for a low-synergy purchase, while its MS and neuro assets could attract bidders, he said. 

Price Action

Biogen shares were trading up more than 2 percent at the time of publication Wednesday at $267.83. 

Related Links:

Mizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen

Pharma M&A Picks Up Momentum

Photo via Wikimedia. 

Latest Ratings for BIIB

DateFirmActionFromTo
Feb 2021Cantor FitzgeraldMaintainsNeutral
Feb 2021Credit SuisseMaintainsOutperform
Feb 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Baird Equity Research Brian SkorneyAnalyst Color Biotech Upgrades Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com